M Caglar1, O Kupik2, E Karabulut3, P F Høilund-Carlsen4. 1. Hacettepe University Medical Faculty, Department of Nuclear Medicine, Sihhiye, Ankara 06100, Turkey. Electronic address: mcaglart@gmail.com. 2. Hacettepe University Medical Faculty, Department of Nuclear Medicine, Sihhiye, Ankara 06100, Turkey. 3. Hacettepe University Medical Faculty, Department of Biostatistics, Sihhiye, Ankara 06100, Turkey. 4. Department of Nuclear Medicine, Odense University Hospital, 5000 Odense C, Denmark.
Abstract
AIM: To examine the value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for the detection of bone metastasis in breast cancer patients and assess whether whole body bone scan (BS) with (99m)Tc-methylene diphosphonate provides any additional information. MATERIAL AND METHODS: Study group comprised 150 patients, mean age 52 years (range 27-85) with breast cancer, suspected of having bone metastases. All patients had undergone both FDG-PET/CT and BS with or without single photon emission tomography/computed tomography (SPECT/CT) within a period of 6 weeks. The final diagnosis of bone metastasis was established by histopathological findings, additional imaging, or clinical follow-up longer than 10 months. Cancer antigen 15-3 (CA15-3) and carcinoembryogenic antigen (CEA) were measured in all patients. RESULTS: Histologically 83%, 7% and 10% had infiltrating ductal, lobular and mixed carcinoma respectively. Confirmed bone metastases were present in 86 patients (57.3%) and absent in 64 (42.7%). Mean CA15-3 and CEA values in patients with bone metastases were 74.6ng/mL and 60.4U/mL respectively, compared to 21.3ng/mL and 3.2U/mL without metastases (p<0.001). The sensitivity of FDG-PET/CT for the detection of bone metastases was 97.6% compared to 89.5% with SPECT/CT. In 57 patients, FDG-PET/CT correctly identified additional pulmonary, hepatic, nodal and other soft tissue metastases, not detected by BS. CONCLUSION: Our findings suggest that FDG-PET/CT is superior to BS with or without SPECT/CT.
AIM: To examine the value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for the detection of bone metastasis in breast cancerpatients and assess whether whole body bone scan (BS) with (99m)Tc-methylene diphosphonate provides any additional information. MATERIAL AND METHODS: Study group comprised 150 patients, mean age 52 years (range 27-85) with breast cancer, suspected of having bone metastases. All patients had undergone both FDG-PET/CT and BS with or without single photon emission tomography/computed tomography (SPECT/CT) within a period of 6 weeks. The final diagnosis of bone metastasis was established by histopathological findings, additional imaging, or clinical follow-up longer than 10 months. Cancer antigen 15-3 (CA15-3) and carcinoembryogenic antigen (CEA) were measured in all patients. RESULTS: Histologically 83%, 7% and 10% had infiltrating ductal, lobular and mixed carcinoma respectively. Confirmed bone metastases were present in 86 patients (57.3%) and absent in 64 (42.7%). Mean CA15-3 and CEA values in patients with bone metastases were 74.6ng/mL and 60.4U/mL respectively, compared to 21.3ng/mL and 3.2U/mL without metastases (p<0.001). The sensitivity of FDG-PET/CT for the detection of bone metastases was 97.6% compared to 89.5% with SPECT/CT. In 57 patients, FDG-PET/CT correctly identified additional pulmonary, hepatic, nodal and other soft tissue metastases, not detected by BS. CONCLUSION: Our findings suggest that FDG-PET/CT is superior to BS with or without SPECT/CT.
Keywords:
Bone metastasis; Bone scintigraphy; Breast cancer; Cáncer de mama; FDG; Gammagrafía ósea; Imaging; Imágenes; Metástasis ósea; PET/CT; PET/TAC
Authors: Christopher C Riedl; Katja Pinker; Gary A Ulaner; Leonard T Ong; Pascal Baltzer; Maxine S Jochelson; Heather L McArthur; Mithat Gönen; Maura Dickler; Wolfgang A Weber Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-01 Impact factor: 9.236
Authors: Sarah Lindgren Belal; May Sadik; Reza Kaboteh; Nezar Hasani; Olof Enqvist; Linus Svärm; Fredrik Kahl; Jane Simonsen; Mads H Poulsen; Mattias Ohlsson; Poul F Høilund-Carlsen; Lars Edenbrandt; Elin Trägårdh Journal: EJNMMI Res Date: 2017-02-16 Impact factor: 3.138